Common use of ABOUT THIS PROSPECTUS SUPPLEMENT Clause in Contracts

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the terms of the offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectus. The second part is the accompanying prospectus, which provides more general information. Generally, when we refer to this “prospectus,” we are referring to both documents combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplement. We urge you to carefully read this prospectus supplement and the accompanying prospectus and any related free writing prospectus, together with the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information that we have provided or incorporated by reference in this prospectus supplement and the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not, and Agent has not, authorized anyone to provide you with different information. No other dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.” As used in this prospectus supplement, the terms “we”, “us”, “our”, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark owner.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in consists of two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the specific terms of the offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectusthis offering. The second part is the accompanying prospectus, which provides is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes more general information. Generally, when we refer some of which may not apply to this “prospectus,” offering. Under this shelf registration process, we may from time to time sell up to 5,000,000 of our ordinary shares, par value NIS 0.0000769 per share under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. The maximum offering price under this prospectus supplement shall not exceed the amount available under our prospectus filed on Form F-3 on July 13, 2020. Before buying any of the ordinary shares that we are referring offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents combinedcontain important information that you should consider when making your investment decision. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any earlier dated document incorporated by reference thereinin this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or , provided that if any statement in one of these documents filed after the date hereof that are deemed is inconsistent with a statement in another document having a later date—for example, a document incorporated by reference herein may modify and supersede the information in this prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statement. We urge you have not authorized anyone to carefully read this prospectus supplement and the accompanying prospectus and provide any related free writing prospectus, together with the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information other than that we have provided contained in or incorporated by reference in this prospectus supplement and supplement, the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to youfiled by us with the SEC. We have not, and Agent X. Xxxxx Securities has not, authorized anyone to provide you with different information. No We take no responsibility for, and provide no assurance as to the reliability of any other dealer, salesperson information that others may give you. This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other person is authorized to give any information or to represent anything not contained than the securities described in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under or the solicitation of an offer to buy such securities in any circumstances and in jurisdictions where it which such offer or solicitation is lawful to do sounlawful. You should assume that the information appearing in this prospectus supplement supplement, the documents incorporated by reference and the accompanying prospectus or any related free writing prospectus is are accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also read and consider the date on information in the front of the document and that any information documents to which we have incorporated by reference is accurate only as of referred you in the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading sections entitled “Where You Can Find More Information.” As used and “Incorporation by Reference” in this prospectus supplement. Unless otherwise indicated, all references to the terms “Company,” “we”, ,” “us”, ,” “our”, “Company”, “Monopar Therapeutics” and “MonoparEntera” refer to Monopar Therapeutics Entera Bio Ltd. and its wholly owned subsidiary, Entera Bio Inc., a Delaware corporation, unless the context otherwise requires. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Various statements in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not be different, and historic results referred to in this Annual Report may be interpreted differently in light of additional research and clinical and preclinical trials results. Forward-looking statements include all statements that are not historical facts. We own or have rights to trademarks or trade names based these forward-looking statements largely on our management’s current expectations and future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this report regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management are forward- looking statements. These statements are subject to risks and uncertainties and are based on information currently available to our management. Words such as, but not limited to, “anticipate,” “believe,” “contemplates,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “likely,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will,” “would,” “seek,” “should,” “target,” or the negative of these terms and similar expressions or words, identify as forward-looking statements. The events and circumstances reflected in our forward-looking statements may not occur and actual results could differ materially from those projected in our forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to: • the scope, progress and costs of developing our product candidates such as EB613 for Osteoporosis and EB612 for Hypoparathyroidism, including without limitation any changes to the design of the ongoing Phase 2 clinical trial of EB613 or the need for additional clinical trials or development work based on further analysis of the interim data from the ongoing EB613 Phase 2 clinical trial; • the accuracy of our estimates regarding expenses, capital requirements, the sufficiency of our cash resources and the need for additional financing; • our ability to raise additional funds on commercially reasonable terms; • our ability to develop, advance product candidates into, and successfully complete, clinical studies such as our ongoing Phase 2 clinical trial of EB613 in osteoporosis; • our reliance on third parties to conduct our clinical trials and on third-party suppliers to supply or produce our product candidates; • our interpretation of FDA feedback and guidance and how such guidance may impact our clinical development plans, specifically our ability to utilize the 505(b)(2) pathway for the development and potential approval of EB613 and any other product candidates we may develop; • our expectations regarding licensing, business transactions and strategic collaborations, including our ongoing collaboration with Amgen; • our ability to use and expand our drug delivery technology to additional product candidates; • our operation as a development stage company with limited operating history and a history of operating losses and our ability to fund our operations going forward; • our ability to continue as a going concern absent access to sources of liquidity; • our ability to obtain and maintain regulatory approval for any of our product candidates; • our competitive position, especially with respect to Forteo® and other products on the market or in conjunction development for the treatment of osteoporosis; • our ability to establish and maintain development and commercialization collaborations; • any potential commercial launch of current or future product candidates, and the timing, cost or other aspects of such commercialization; • our ability to manufacture and supply sufficient amounts of material to support our clinical trials and any potential future commercial requirements; • the safety and efficacy of therapeutics marketed by competitors that are targeted toward indications for which we are developing product candidates; • the size of any market we may target and the adoption of our product candidates, if approved, by physicians and patients; • our ability to obtain, maintain and protect our intellectual property and operate our business without infringing misappropriating or otherwise violating any intellectual property rights of others; • our ability to retain key personnel and recruit additional qualified personnel; • the possibility that competing products or technologies may make any product candidates we may develop and commercialize or our oral delivery technology obsolete; • the pricing and reimbursement of our product candidates, if approved; • our ability to develop a sales, marketing and distribution infrastructure, if any; • our ability to manage growth; and • the duration and severity of the recent coronavirus (COVID-19) outbreak, the actions that may be required to contain the coronavirus or treat its impact, and its impact on our operations and workforce, including our research and development and clinical trials. All written and verbal forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We caution investors not to rely too heavily on the forward-looking statements we make or that are made on our behalf. Except as required by law, we are under no duty, and expressly disclaim any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in any annual, quarterly or current reports that we may file with the operation of our businessSecurities and Exchange Commission. Each trademark, trade name There can be no assurance that the actual results or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display developments anticipated by us of other parties’ trademarkswill be realized or, trade names or service marks is not intended to and does not imply a relationship witheven if substantially realized, that they will have the expected consequences to, or endorsement or sponsorship by us ofeffects on us. Therefore, no assurance can be given that the trademark, trade name or service mark owneroutcomes stated in such forward-looking statements and estimates will be achieved.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the specific terms of the this offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part is part, the accompanying prospectus, which provides gives more general information, some of which may not apply to this offering. Generally, when we refer to this “prospectus,” , we are referring to both documents parts of this document combined. To the extent there is a conflict between the information contained in In this prospectus supplement, on as permitted by law, we “incorporate by reference” information from other documents that we file with the one hand, and the SEC. This means that we can disclose important information contained in the accompanying prospectus or any earlier dated document to you by referring you to those documents. The information incorporated by reference therein, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplement. We urge you is considered to carefully read be a part of this prospectus supplement and the accompanying prospectus and any related free writing prospectus, together should be read with the same care. When we update the information contained in documents that have been incorporated herein and therein by reference as described under by making future filings with the heading “Incorporation SEC, the information included or incorporated by reference in this prospectus supplement is considered to be automatically updated and superseded. In other words, in case of Information a conflict or inconsistency between information contained in this prospectus supplement and information in the accompanying prospectus or incorporated by Reference,” before buying any of our Common Stock being offeredreference into this prospectus supplement, you should rely on the information contained in the document that was filed later. You should rely only on the information that we have provided or incorporated by reference contained in this prospectus supplement and the accompanying prospectus prospectus, including the information incorporated by reference herein as described under “Where You Can Find More Information; Incorporation of Documents by Reference,” and any related free writing prospectus that we prepare and distribute. We have not authorized anyone to provide you with information other than that contained in or incorporated by reference into this prospectus supplement, the accompanying prospectus or any free writing prospectus related hereto that we may authorize to be provided delivered to you. If given or made, any such other information or representation should not be relied upon as having been authorized by us. We have notmay only offer to sell, and Agent has not, authorized anyone seek offers to provide you with different informationbuy any securities in jurisdictions where offers and sales are permitted. No other dealer, salesperson This prospectus supplement and the accompanying prospectus supplement or other person is authorized offering materials do not contain all of the information included in the registration statement as permitted by the rules and regulations of the SEC. For further information, we refer you to give any the registration statement on Form S-3, including its exhibits. We are subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and, therefore, file reports and other information or to represent anything not with the SEC. Statements contained in this prospectus supplement and the accompanying prospectus or other offering materials about the provisions or contents of any related free writing prospectus agreement or other document are only summaries. If SEC rules require that we may authorize any agreement or document be filed as an exhibit to be provided the registration statement, you should refer to you. You must not rely on any unauthorized information that agreement or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do sodocument for its complete contents. You should assume that the information in this prospectus supplement and supplement, the accompanying prospectus or any related free writing prospectus other offering materials is only accurate only as of the date on the front of the document its respective cover, and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless unless otherwise indicated. Our business, financial condition, results of the time of delivery of this prospectus supplement operations and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein prospects may have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Informationchanged since such date.” As used in this prospectus supplement, the terms “we”, “us”, “our”, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark owner.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we have filed with the U.S. Securities and Exchange Commission (Commission, or the “SEC”), utilizing a “shelf” registration process. Under the By using a shelf registration processstatement, we may offer and sell shares of our common stock having an aggregate offering price of up to $50 million from time to time in one or more offerings under this prospectus supplement at prices and on terms to be determined by market conditions at the time of offering. We provide information to you about this offering of our Common Stock described in the accompanying prospectus. This document is common stock in two parts. The first part is separate documents that are bound together: (1) this prospectus supplement, which describes our Common Stock we are offering the specific details regarding this offering; and the terms of the offering and also adds to and updates information contained in (2) the accompanying prospectus and the documents incorporated by reference into the accompanying prospectus. The second part is the accompanying base prospectus, which provides more general information, some of which may not apply to this offering. Generally, when we refer to this “prospectusprospectus supplement,” we are referring to both documents combined. If information in this prospectus supplement is inconsistent with the accompanying base prospectus, you should rely on this prospectus supplement. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference thereinin this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or If any statement in one of these documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information is inconsistent with a statement in this prospectus supplement. We urge you to carefully read this prospectus supplement and the accompanying prospectus and any related free writing prospectusanother document having a later date—for example, together with the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information that we have provided or a document incorporated by reference in this prospectus supplement and supplement—the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to youstatement in the document having the later date modifies or supersedes the earlier statement. We have not, and Agent has the Agents have not, authorized anyone to provide you with different information. No information other dealer, salesperson or other person is authorized to give any information or to represent anything not than that contained in this prospectus supplement supplement, the accompanying base prospectus and any free writing prospectus. We are not, and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is Agents are not, making an offer to sell only our Common Stock offered hereby and only under circumstances and or soliciting any offer to buy these securities in jurisdictions any jurisdiction where the offer or sale is not permitted or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is lawful unlawful to do somake an offer or solicitation. You should assume that the information appearing in this prospectus supplement and supplement, the accompanying prospectus or base prospectus, the documents incorporated by reference herein and therein and any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference authorized for use in connection with this offering is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement, the document accompanying base prospectus, the documents incorporated by reference, regardless of the time of delivery of this prospectus supplement reference herein and the accompanying prospectus or therein and any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains summaries of certain provisions contained that we have authorized for use in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified connection with this offering in their entirety by the actual documentsbefore making an investment decision. Copies of some Before buying any of the documents referred common stock that we are offering, we urge you to herein have been filedcarefully read this prospectus supplement, will be filed or will be the accompanying base prospectus and all of the information incorporated by reference herein and therein, as exhibits to well as the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as additional information described below under the heading “Where You Can Find More Information; Incorporation by Reference.” As These documents contain important information that you should consider when making your investment decision. We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement outside the United States. This prospectus supplement does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. When we refer to “Cerecor,” “Company,” “we,” “our” and “us” in this prospectus supplement, the terms “we”we mean Cerecor Inc. or its consolidated subsidiaries, “us”, “our”, “Company”, “Monopar Therapeutics” and “Monopar” unless otherwise specified. When we refer to Monopar Therapeutics Inc.“you,” we mean the holders of the applicable series of securities. This prospectus supplement includes our trademarks and trade names, a Delaware corporationincluding, without limitation, CERECOR and our logo, which are our property and are protected under applicable intellectual property laws. We own or have rights to trademarks or This prospectus supplement also contains trademarks, trade names that we use in conjunction with and service marks of other companies, which are the operation property of our businesstheir respective owners. Each trademarkSolely for convenience, trademarks, trade name or names and service mark of any other company appearing marks referred to in this prospectus supplement may appear without the ®, ™ or SM symbols, but such references are not intended to indicate, in any way, that we or the accompanying prospectus belongs applicable owner will not assert, to the fullest extent permitted under applicable law, our or its holderrights or the right of any applicable licensor to these trademarks, trade names and service marks. Use We do not intend our use or display by us of other parties’ trademarks, trade names or service marks is to imply, and such use or display should not intended be construed to and does not imply imply, a relationship with, or endorsement or sponsorship by of us ofby, the trademark, trade name or service mark ownerthese other parties.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, base prospectus are part of a registration statement on Form S-3 F-3 (File Registration No. 333-235791251304) that we filed with the Securities and Exchange Commission (the “"SEC”), utilizing ) using a “"shelf” registration process. Under the shelf this "shelf” registration process, we may offer and sell may, from time to time time, sell or issue any of the combination of securities described in the accompanying base prospectus in one or more offerings our Common Stock described in the accompanying prospectus. This document is in two partswith a maximum aggregate offering price of up to US $80,000,000. The first part is accompanying base prospectus provides you with a general description of us and the securities we may offer, some of which do not apply to this offering. Each time we sell securities, we provide a prospectus supplement, which describes our Common Stock we are offering and supplement that contains specific information about the terms of the offering and that offering. A prospectus supplement may also adds to and updates add, update, or change information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying base prospectus. The second part is This prospectus supplement relates to the accompanying prospectus, which provides more general information. Generally, when we refer to this “prospectus,” we are referring to both documents combinedoffering of our Ordinary Shares. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, supplement and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on the other handbase prospectus, you should rely on the information in this prospectus supplement. Additional This prospectus supplements or supplement, the accompanying base prospectus, and the documents filed after the date hereof that are deemed incorporated we incorporate by reference herein may modify and supersede the therein include important information in this prospectus supplementabout us and our Ordinary Shares and other information you should know before investing. We urge you to carefully You should read both this prospectus supplement and the accompanying prospectus and any related free writing base prospectus, together with the additional information incorporated herein and therein by reference as described below under the heading “Incorporation of Information by Reference,"Where You Can Find Additional Information.” before buying any of our Common Stock being offered. You should rely only on the information that we have provided contained in or incorporated by reference in this prospectus supplement and supplement, the accompanying prospectus base prospectus, and any related free writing prospectus that prepared by or on behalf of us or to which we may authorize to be provided to have referred you. We have not, and Agent AGP has not, authorized anyone to provide you with different information. No other dealerIf anyone provides you with different or inconsistent information, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must you should not rely on any unauthorized information or representationit. This prospectus supplement We are not, and AGP is not, making an offer to sell only our Common Stock offered hereby and only under circumstances and these securities in jurisdictions any jurisdiction where the offer or sale is not permitted or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is lawful unlawful to do somake an offer or solicitation. You should assume that the information appearing in this prospectus supplement supplement, the accompanying base prospectus, and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have documents incorporated by reference herein and therein is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should carefully read this entire prospectus supplement and the accompanying base prospectus, including the information included and referred to under "Risk Factors” below, the information incorporated by reference in this prospectus supplement and in the accompanying base prospectus, and the financial statements and the other information incorporated by reference in the accompanying base prospectus, before making an investment decision. Unless otherwise stated in this prospectus supplement, "we,” "us,” "our,” or "our company,” refers to VivoPower International PLC, our subsidiaries, and our predecessor operations. NOTEON FORWARD-LOOKING STATEMENTS The statements contained in this prospectus supplement and accompanying prospectus and the documents incorporated by reference herein include forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Words such as, but not limited to, "believe,” "expect,” "anticipate,” "estimate,” "intend,” "may,” "plan,” "potential,” "predict,” "project,” "targets,” "likely,” "will,” "would,” "could,” "should,” "continue,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus supplement and incorporated by reference in the prospectus, we caution you that these statements are based on our projections of the future that are subject to known and unknown risks and uncertainties and other factors that may cause our actual results, level of activity, performance or achievements expressed or implied by these forward-looking statements, to differ. The sections in our periodic reports, including our Annual Report on Form 20-F for the fiscal year ended June 30, 2021, titled "Business,” "Risk Factors,” and "Operating and Financial Review and Prospects,” as well as other sections in this prospectus supplement and accompany prospectus and the documents or reports incorporated by reference in the prospectus, discuss some of the factors that could contribute to these differences. These forward-looking statements include, among other things, statements about: ● our expectations regarding our revenue, expenses and other results of operations; ● our plans to acquire, invest in, develop or sell our investments in energy projects or joint ventures, including in the electric vehicle sector; ● our ability to attract and retain customers; ● the growth rates of the markets in which we compete; ● our liquidity and working capital requirements; ● our ability to raise sufficient capital to realize development opportunities and thereby generate revenue; ● our anticipated strategies for growth; ● our ability to anticipate market needs and develop new and enhanced solutions to meet those needs; ● anticipated trends and challenges in our business and in the markets in which we operate; ● our expectations regarding demand for solar power by energy users or investor in projects; ● our expectations regarding changes in the cost of developing and constructing solar projects; ● our ability to compete in our industry and innovation by our competitors; ● the extent to which the COVID-19 pandemic affects our business, financial condition and results of operations; ● our expectations regarding our ongoing legal proceedings; ● our ability to adequately protect our intellectual property; and ● our plans to pursue strategic acquisitions. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important cautionary statements in this prospectus supplement, the accompanying prospectus or in the documents incorporated by reference in the prospectus, particularly in the "Risk Factors” section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. For a summary of such factors, please refer to the section titled "Risk Factors” in this prospectus supplement, the accompanying prospectus, as updated and supplemented by the discussion of risks and uncertainties under "Risk Factors” contained in our most recent Annual Report on Form 20-F, as revised or supplemented by our subsequent periodic reports filed under the Exchange Act, as well as any amendments thereto, as filed with the SEC and which are incorporated by reference. The information contained in this document is believed to be current as of the date of this document. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this prospectus or in any document incorporated herein by reference might not occur. Investors are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this prospectus or the date of the document incorporated by reference. We are not under any obligation, regardless and we expressly disclaim any obligation, to update or alter any forward- looking statements, whether as a result of the time of delivery of this prospectus supplement and the accompanying prospectus new information, future events or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete informationotherwise. All of the summaries subsequent forward-looking statements attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the actual documents. Copies of some of the documents cautionary statements contained or referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.” As used in this prospectus supplement, the terms “we”, “us”, “our”, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark ownersection.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are the specific terms of this offering and the terms of the offering securities offered hereby, and also adds to and updates information contained in the accompanying prospectus and the documents incorporated into each by reference into the accompanying prospectusreference. The second part is the accompanying prospectus, which provides more general information, some of which may not apply to this offering of common stock. Generally, when This prospectus supplement is deemed to be incorporated by reference into the accompanying prospectus solely for the purpose of this offering. When we refer only to this the “prospectus,” we are referring to both documents parts combined. To the extent If there is a conflict an inconsistency between the information contained in this prospectus supplement, on the one hand, supplement and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on the other handprospectus, you should rely on the information in this prospectus supplement. Additional You should rely only on the information contained in this prospectus supplements or supplement, the accompanying prospectus and the documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplementor therein. We urge have not authorized any other person to provide you with different or additional information. If anyone provides you with different or additional information, you should not rely on it. This prospectus supplement and the accompanying prospectus do not constitute an offer to carefully read sell or a solicitation of an offer to buy any securities other than the registered securities to which they relate, and this prospectus supplement and the accompanying prospectus and do not constitute an offer to sell or the solicitation of an offer to buy securities in any related free writing prospectusjurisdiction where, together with the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying or to any of our Common Stock being offeredperson to whom, it is unlawful to make such an offer or solicitation. You should rely only on not assume that the information that we have provided or incorporated by reference in this prospectus supplement and the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not, and Agent has not, authorized anyone to provide you with different information. No other dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely is correct on any unauthorized information or representation. This date after the respective dates of the prospectus supplement is an offer and the accompanying prospectus, as applicable, even though this prospectus supplement and the accompanying prospectus are delivered or securities are sold pursuant to sell only our Common Stock offered hereby the prospectus and only under circumstances and in jurisdictions where it is lawful to do sosuch prospectus supplement or supplements at a later date. You should assume that the information appearing in this prospectus supplement and supplement, the accompanying prospectus or any related free writing prospectus is accurate only as of and the date on the front of the document and that any information we have documents incorporated into each by reference is accurate only as of the date respective dates of the document incorporated by referenceapplicable documents. Our business, regardless financial condition, results of the time of delivery of operations and prospects may have changed since those dates. You should read this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains summaries of certain provisions contained in some of together with the documents additional information described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading headings “Where You Can Find More Information.” As used and “Incorporation of Certain Information by Reference” before investing in our common stock. Unless otherwise indicated or the context requires otherwise, references in this prospectus to “GameStop,” the “Company,” “we,” “us,” “our” or comparable terms are to GameStop Corp., a Delaware corporation, and its consolidated subsidiaries. The distribution of this prospectus supplement, the terms accompanying prospectus and any authorized “we”, “us”, “our”, “Company”, “Monopar Therapeuticsfree writing prospectus” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation offering of the shares of our businesscommon stock may be restricted by law. Each trademark, trade name or service mark of any other company appearing in If you possess this prospectus supplement or supplement, the accompanying prospectus belongs or any authorized “free writing prospectus,” you should find out about and observe these restrictions. This prospectus supplement, the accompanying prospectus and any authorized “free writing prospectus” are not an offer to its holder. Use sell the shares and are not soliciting an offer to buy the shares in any jurisdiction where the offer or display by us of other parties’ trademarks, trade names or service marks sale is not intended permitted or where the person making the offer or sale is not qualified to and does do so or to any person to whom it is not imply a relationship with, permitted to make such offer or endorsement or sponsorship by us of, the trademark, trade name or service mark ownersale.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in two parts. The first part is this the prospectus supplement, which describes our Common Stock we are offering and the specific terms of the this offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectus. The second part is the accompanying prospectus, which provides gives more general information. Generally, when we refer some of which may not apply to this “prospectus,” we are referring to both documents combinedoffering. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, supplement and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference thereinprospectus, on the other hand, you should rely on the information in this prospectus supplementsupplement shall control. Additional prospectus supplements In addition, any statement in a filing we make with the SEC that adds to, updates or documents filed after changes information contained in an earlier filing we made with the date hereof that are SEC shall be deemed incorporated by reference herein may to modify and supersede the such information in this prospectus supplementthe earlier filing. We urge you to carefully You should read this prospectus supplement and the accompanying prospectus and any related free writing prospectus, document together with the additional information incorporated herein and therein by reference as described under the heading “Where You Can Find More Information and Incorporation of Information by Reference,” before buying any of our Common Stock being offeredin this prospectus supplement. You should rely only on the information that we have provided contained or incorporated by reference in this prospectus supplement and the accompanying prospectus and any related free writing prospectus that accompany prospectus. Neither we may authorize to be provided to you. We have not, and Agent nor the sales agent has not, authorized anyone to provide you with different information. No other dealerIf anyone provides you with different or inconsistent information, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must you should not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do soit. You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus prospectus, as well as the information we have previously filed with the SEC and incorporated by reference in this document, is accurate only as of its date or the date on the front of the document and that any information we have incorporated by reference is accurate only dates which are specified in those documents, as of the date of the document incorporated by referenceapplicable, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.” As used in this prospectus supplement, the terms “we”, “us”, “our”, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation shares of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark ownercommon stock.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, prospectus are part of a “shelf” registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (Commission, or the “SEC”), utilizing a “shelf” registration process. Under on November 24, 2020, and which was declared effective by the shelf registration processSEC on December 22, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus2020. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the terms of the this offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus and the accompanying prospectus. The second part is the accompanying prospectus, which provides gives more general information. Generallyinformation about the shares of our common stock and other securities we may offer from time to time under our shelf registration statement, when we refer some of which does not apply to the securities offered by this “prospectus,” we are referring to both documents combinedprospectus supplement. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in You should read this prospectus supplement. We urge you to carefully read this prospectus supplement and , the accompanying prospectus and any related free writing prospectus, together with the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information that we have provided or documents incorporated by reference in this prospectus supplement and the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not, and Agent has not, authorized anyone to provide you with different information. No other dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is before making an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do soinvestment decision. You should assume that also read and consider the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of documents referred to in the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery sections of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading entitled “Where You Can Find More Information” and “Incorporation of Certain Documents by Reference.” As used in In this prospectus supplementsupplement and the accompanying prospectus, unless otherwise indicated, the terms “Sonoma,” “we”, ,” “us”, ,” “our”, “Company”, “Monopar Therapeutics,” and “Monopar” similar terms refer to Monopar Therapeutics Inc.Sonoma Pharmaceuticals, Inc. and its subsidiaries on a Delaware corporationconsolidated basis. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark owner.S-1

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement document is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (Commission, or the “SEC”), utilizing using a “shelf” registration process. Under the shelf registration process, we may offer process and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in consists of two parts. The first part is this prospectus supplement, including the documents incorporated by reference, which describes our Common Stock we are offering and the specific terms of the this offering and also adds to and updates information contained in the accompanying prospectus. Under this prospectus supplement, we may from time to time sell ADSs representing our ordinary shares having an aggregate offering price of up to $75 million in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act. The second part, the accompanying prospectus, including the documents incorporated by reference, gives more general information, some of which may not be applicable to this offering. Generally, when we refer to the “prospectus” we are referring to both parts combined. If information in this prospectus supplement is inconsistent with the accompanying prospectus or with any document incorporated by reference that was filed with the SEC before the date of this prospectus supplement, you should rely on this prospectus supplement. If any statement in this prospectus supplement or the accompanying prospectus is inconsistent with a statement in another document that is incorporated by reference into this prospectus and having a later date, the statement in the document having the later date modifies or supersedes the earlier statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. This prospectus supplement, the accompanying prospectus and the documents incorporated by reference into each include important information about us, the accompanying prospectusADSs being offered and other information that you should know before investing in our ADSs. The second part is the accompanying prospectus, which provides more general information. Generally, when we refer to this “prospectus,” we are referring to both documents combined. To the extent there is a conflict between the You should also read and consider information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplement. We urge we have referred you to carefully read in the sections of this prospectus supplement and the accompanying prospectus and any related free writing prospectus, together with the information incorporated herein and therein by reference as described under the heading entitled “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. and “Where You should rely only on the information that we have provided or incorporated by reference in this prospectus supplement and the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not, and Agent has not, authorized anyone to provide you with different information. No other dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. Can Find More Information.” You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the respective document and that any information that we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement or the accompanying prospectus or the time of any sale of an ADS. Our business, financial condition, liquidity, results of operations and prospects may have changed since those dates. This prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains contain summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated herein by reference as exhibits to the registration statement of which this prospectus supplement is a partstatement, and you may obtain copies of those documents as described below under the heading sections entitled “Incorporation of Information by Reference” and “Where You Can Find More Information.” As used We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. Neither we nor SVB Securities are making offers to sell or solicitations to buy our ADSs in any jurisdiction in which an offer or solicitation is not permitted or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. For investors outside the United States: Neither we nor SVB Securities have done anything that would permit this offering or possession or distribution of this prospectus supplement in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus supplement must inform themselves about, and observe any restrictions relating to, the offering of the securities described herein and the distribution of this prospectus supplement outside the United States. Unless otherwise indicated or the context otherwise requires, references in this prospectus supplement, to “Innate,” “the terms Company,” “we”, ,” “us”, “our”, “Company”, “Monopar Therapeutics,” and “Monoparour” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to Innate Pharma S.A. and its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark ownerconsolidated subsidiary.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement document is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), utilizing ) using a “shelf” registration process. Under the shelf registration process, we may offer process and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in consists of two parts. The first part is this prospectus supplement, including the documents incorporated by reference, which describes our Common Stock the specific terms of this offering. The second part, the accompanying prospectus, including the documents incorporated by reference, gives more general information, some of which may not apply to this offering. Generally, when we refer to the “prospectus,” we are referring to both parts combined. This prospectus relates to the offering of our common stock. Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus, together with the information incorporated by reference as described under the headings “Where You Can Find More Information” and “Incorporation by Reference” in this prospectus, and any free writing prospectus or prospectus supplement that we have authorized for use in connection with this offering. These documents contain important information that you should consider when making your investment decision. This prospectus describes the terms of the this offering of common stock and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying this prospectus. The second part is the accompanying prospectus, which provides more general information. Generally, when we refer to this “prospectus,” we are referring to both documents combined. To the extent there is a conflict between If the information contained in this prospectus supplement, on the one hand, and differs or varies from the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on herein that was filed with the other handSEC before the date of this prospectus, you should rely on the information set forth in this prospectus supplementprospectus. Additional prospectus supplements or If any statement in one of these documents is inconsistent with a statement in another document having a later date (for example, a subsequently filed after the date hereof that are document deemed incorporated by reference herein may modify and supersede the information in this prospectus supplementprospectus), the statement in the document having the later date modifies or supersedes the earlier statement. We urge you Any statement so modified or superseded will not be deemed, except as so modified or superseded, to carefully read constitute a part of this prospectus supplement and the accompanying prospectus and any related free writing prospectus, together with the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information that we have provided contained or incorporated by reference in this prospectus supplement and the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to youprospectus. We have not, and Agent the sales agent has not, authorized anyone to provide you with information that is in addition to or different informationfrom that contained or incorporated by reference in this prospectus or contained in any permitted free writing prospectuses we have authorized for use in connection with this offering. No We and the sales agent take no responsibility for, and can provide no assurance as to the reliability of, any other dealer, salesperson or other person is authorized to give any information or to represent anything not that others may provide. The information contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus documents incorporated by reference herein is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by referencetheir respective dates, regardless of the time of delivery of this prospectus supplement and any such document or the accompanying prospectus or any related free writing prospectus, or time of any sale of our Common Stockcommon stock. This prospectus supplement contains summaries Our business, financial condition, results of certain provisions operations and prospects may have changed since those dates. It is important for you to read and consider all information contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which in this prospectus supplement is a partin making your investment decision. You should read this prospectus, and you may obtain copies of those as well as the documents as incorporated by reference herein, the additional information described below under the heading section titled “Where You Can Find More Information.” and “Incorporation of Certain Documents by Reference” in this prospectus and any free writing prospectus that we have authorized for use in connection with this offering, before investing in our common stock. We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. We use various trademarks and trade names in our business, including without limitation our corporate name and logo. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. This prospectus and the documents incorporated by reference herein also contain estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where such offers and sales are permitted. The distribution of this prospectus and the offering of our common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our common stock and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. As used in this prospectus supplementprospectus, unless the terms context otherwise requires, references to the “company,” “we”, ,” “us”, “our”, “Company”, “Monopar Therapeutics,” and “Monoparour” refer to Monopar Therapeutics Aptinyx Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark owner.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, base prospectus are part of a registration statement on Form S-3 (File No. 333-235791) that we have filed with the U.S. Securities and Exchange Commission (Commission, or the “SEC”), utilizing a “shelf” registration process. Under the By using a shelf registration processstatement, we may offer and sell shares of our common stock having an aggregate offering price of up to $20,000,000 from time to time in one or more offerings our Common Stock described in under this prospectus supplement and the accompanying prospectusprospectus pursuant to the Sales Agreement between the Company and Maxim. This document is We provide information to you about this offering in two partsseparate documents that are bound together. The first part is consists of this prospectus supplement, which describes our Common Stock we are offering and the terms of the offering and also adds to and updates provides you with specific information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectusabout this offering. The second part is part, the accompanying base prospectus, which provides more general information, some of which may not apply to this offering. Generally, when we refer only to this the “prospectus,” we are referring to both documents combined. To the extent there is a conflict between the information contained in this This prospectus supplementsupplement may add, on the one hand, and the update or change information contained in the accompanying prospectus or base prospectus. If any earlier dated document incorporated by reference therein, on the other hand, you should rely on the information statement we make in this prospectus supplement. Additional prospectus supplements or documents filed after supplement is inconsistent with statements made in the date hereof that are deemed incorporated by reference herein may modify and supersede accompanying base prospectus, the information statements made in this prospectus supplement. We urge you supplement will be deemed to carefully read this prospectus supplement and modify or supersede those made in the accompanying prospectus and base prospectus. However, if any related free writing prospectusstatement in one of these documents is inconsistent with a statement in another document having a later date—for example, together with the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information that we have provided or a document incorporated by reference in this prospectus supplement and the accompanying prospectus —the statement in the document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects may have changed since the earlier dates. We and Maxim have not authorized anyone to provide you with any related information or to make any representations other than those contained in this prospectus supplement, the accompanying base prospectus or any free writing prospectuses prepared by or on behalf of us or to which we or Maxim have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and Maxim are not making an offer to sell or soliciting an offer to buy our securities in any jurisdiction where an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should read this prospectus supplement and the accompanying prospectus, the documents incorporated by reference herein and therein and any free writing prospectus that we may authorize for use in connection with this offering in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the section of this prospectus supplement and the accompanying prospectus titled “Where You Can Find More Information; Incorporation By Reference.” The industry and market data and other statistical information contained in the documents we incorporate by reference are based on our own estimates, independent publications, government publications, reports by market research firms or other published independent sources, and, in each case, are believed by us to be provided to youreasonable estimates. We Although we believe these sources are reliable, we have not, and Agent has not, authorized anyone to provide you with different not independently verified the information. No other dealerWhen we refer to “NuZee,” “we,” “our,” “us” and the “Company” in this prospectus supplement and the accompanying prospectus, salesperson we mean NuZee, Inc. and its subsidiaries on a consolidated basis, unless otherwise specified. This prospectus supplement and the accompanying prospectus may include trademarks, service marks and trade names owned by us or other person is authorized to give any information or to represent anything not contained companies. All trademarks, service marks and trade names included in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that are the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as property of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Informationrespective owners.” As used in this prospectus supplement, the terms “we”, “us”, “our”, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark owner.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the specific terms of the this offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectusherein. The second part is the accompanying prospectus, which provides more general informationinformation about securities we may offer from time to time, some of which does not apply to this offering. Generally, when we refer to this “prospectus,” , we are referring to both parts of this document combined. This prospectus supplement may add, update or change information contained in the accompanying prospectus and the documents combinedincorporated by reference into this prospectus supplement and accompanying prospectus. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, supplement and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on therein filed prior to the other handdate of this prospectus supplement, you should rely on the information in this prospectus supplement. Additional prospectus supplements or ; provided that if any statement in one of these documents filed after the is inconsistent with a statement in another document having a later date hereof that are deemed — for example, a document incorporated by reference herein may modify and supersede in the accompanying prospectus — the statement in the document having the later date modifies or supersedes the earlier statement. Neither we nor Canaccord has authorized anyone to provide any information in other than that contained or incorporated by reference into this prospectus supplement, the accompanying prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We urge you and Canaccord take no responsibility for, and can provide no assurance as to carefully read the reliability of, any other information that others may give you. This prospectus supplement and the accompanying prospectus do not constitute an offer to sell, or a solicitation of an offer to purchase, the securities offered by this prospectus supplement and the accompanying prospectus and in any related free writing prospectus, together with the jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. The information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information that we have provided or incorporated by reference in this prospectus supplement and the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not, and Agent has not, authorized anyone to provide you with different information. No other dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and or the accompanying prospectus prospectus, or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information incorporated by reference herein or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus therein, is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by referencerespective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or of any sale of our Common StockClass A common stock. This It is important for you to read and consider all information contained in this prospectus supplement contains summaries of certain provisions contained in some of and the accompanying prospectus, including the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits herein and therein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you in the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading sections entitled “Where You Can Find More Information.” As used and “Incorporation of Certain Documents by Reference” in this prospectus supplementsupplement and in the accompanying prospectus. We are offering to sell, and seeking offers to buy, shares of our Class A common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the Class A common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the terms offering of the Class A common stock and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. Unless the context otherwise indicates, references in this prospectus to “Blue Apron,” “the company “ “we”, “us”, ,” “our”, “Company”, “Monopar Therapeutics” and “Monoparus” refer refer, collectively, to Monopar Therapeutics Blue Apron Holdings, Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to and its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark ownerconsolidated subsidiaries.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, prospectus are part of a “shelf” registration statement on Form S-3 (File No. 333-235791234107) that we initially filed with the Securities SEC on October 4, 2019, and Exchange Commission (that was declared effective by the “SEC”)SEC on October 15, utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus2019. This document is in two parts. The first part is this prospectus supplement, which supplement describes our Common Stock we are offering and the terms of the this offering of our common stock and also adds to and updates the information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectus. The second part is part, the accompanying prospectus, which provides more general information, some of which may not apply to this offering. Generally, when we refer to this “prospectus,” , we are referring to both documents parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, supplement and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on the other handprospectus, you should rely on the information in this prospectus supplement. Additional This prospectus supplements or documents filed after supplement and the date hereof that are deemed incorporated by reference herein may modify and supersede accompanying prospectus relate to the information in this prospectus supplementoffering of shares of our common stock. We Before buying any of the shares of common stock offered hereby, we urge you to read carefully read this prospectus supplement and the accompanying prospectus and any related free writing prospectus, together with the information incorporated herein and therein by reference as described below under the heading “Incorporation of Information Certain Documents by Reference,.” before buying any of our Common Stock being offeredThis prospectus supplement contains information about the common stock offered hereby and may add to, update or change information in the accompanying prospectus. You should rely only on the information that we have provided contained in, or incorporated by reference in into, this prospectus supplement and the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to youprospectus. We have not, and Agent Jefferies has not, authorized anyone to provide you with different or additional information. No other dealer, salesperson We are not making offers to sell or other solicitations to buy our common stock in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is authorized not qualified to give any information do so or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize anyone to be provided whom it is unlawful to you. You must not rely on any unauthorized information or representation. This prospectus supplement is make an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do soor solicitation. You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of the date dates on the front of the document respective documents and that any information that we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement or the accompanying prospectus or the time of any sale of a security. This prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains contain summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated herein by reference as exhibits to the registration statement of which this prospectus supplement is a partstatement, and you may obtain copies of those documents as described below under the heading section titled “Where You Can Find More Information.” As used We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. This prospectus supplement and the accompanying prospectus contain and incorporate by reference market data and industry statistics and forecasts that are based on independent industry publications and other publicly-available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus supplement, accompanying prospectus or the terms documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled “Risk Factors” in this prospectus supplement and the accompanying prospectus, and under similar headings in the other documents that are incorporated herein by reference. Accordingly, investors should not place undue reliance on this information. ADMA’s name and logo are either registered trademarks or trademarks of ADMA Biologics, Inc. in the United States and/or other countries. All other trademarks, service marks or other tradenames appearing in this prospectus supplement and the accompanying prospectus are the property of their respective owners. Unless otherwise mentioned or unless the context requires otherwise, all references in this prospectus supplement and the accompanying prospectus to the “Company,” “ADMA,” “we”, ,” “us”, ,” “our”” or similar references mean ADMA Biologics, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation, and its wholly owned subsidiaries, ADMA Plasma Biologics, Inc., a Delaware corporation (“ADMA Plasma Biologics”), ADMA BioCenters Georgia, Inc., a Delaware corporation (“ADMA BioCenters”), and ADMA BioManufacturing, LLC, a Delaware limited liability company (“ADMA BioManufacturing”). We own or have rights to trademarks or This prospectus supplement includes our trademarks, trade names that we use in conjunction with and service marks, such as “ASCENIVTM,” “Nabi-HB®” and “BIVIGAM®,” which are protected under applicable intellectual property laws and are the operation property of our businessADMA Biologics, Inc., or its subsidiaries. Each trademarkSolely for convenience, trademarks, trade name or names and service mark of any other company appearing marks referred to in this prospectus supplement may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the accompanying prospectus belongs right of the applicable licensor to its holderthese trademarks, trade names and service marks. Use We do not intend our use or display by us of other parties’ trademarks, trade names or service marks is to imply, and such use or display should not intended be construed to and does not imply imply, a relationship with, or endorsement or sponsorship by of us ofby, the trademark, trade name or service mark ownerthese other parties.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, base prospectus are part of a registration statement on Form S-3 (File No. 333-235791199446) that we filed with the Securities and Exchange Commission (the “"SEC”), ") utilizing a “"shelf” " registration process. Under the shelf registration process, Each time we may offer and sell from time to time in one or more offerings our Common Stock described in securities under the accompanying prospectus. This document is in two parts. The first part is this base prospectus supplement, which describes our Common Stock we are offering and will provide a prospectus supplement that will contain specific information about the terms of that offering, including the price, the amount of securities being offered and the plan of distribution. The shelf registration statement was initially filed with the SEC on October 17, 2014, and was declared effective by the SEC on September 2, 2016. This prospectus supplement describes the specific details regarding this offering and also adds to and updates may add, update or change information contained in the accompanying base prospectus. The accompanying base prospectus provides general information about us, some of which, such as the section entitled "Plan of Distribution," may not apply to this offering. Generally, when we refer to this "prospectus," we are referring to both documents combined. If information in this prospectus supplement is inconsistent with the accompanying base prospectus or the information incorporated by reference, you should rely on this prospectus supplement. This prospectus supplement, together with the accompanying base prospectus and the documents incorporated by reference into the accompanying prospectus. The second part is the accompanying prospectus, which provides more general information. Generally, when we refer to this “prospectus,” we are referring to both documents combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplement. We urge you to carefully read this prospectus supplement and the accompanying base prospectus and any related free writing prospectus, together includes all material information relating to this offering. We have not authorized anyone to provide you with the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offereddifferent or additional information. If anyone provides you with different or inconsistent information, you should not rely on it. You should rely only on assume that the information that we have provided or appearing in this prospectus supplement, the accompanying base prospectus, any related free writing prospectus, and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not, and Agent has not, authorized anyone to provide you with different information. No other dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing base prospectus is accurate only as of the date on respective dates of those documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should carefully read this prospectus supplement, the front of accompanying base prospectus, the information and documents incorporated herein and therein by reference, any related free writing prospectus, and the additional information under the heading "Where You Can Find More Information" before making an investment decision . We are not, and the Agent is not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document and that any information we have is incorporated by reference is into this prospectus supplement or the accompanying base prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date of when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the document incorporated by reference, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale current state of our Common Stockaffairs. This prospectus supplement contains summaries of certain provisions contained in some of Unless otherwise mentioned or unless the documents described hereincontext requires otherwise, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.” As used all references in this prospectus supplement, to "Netlist," "the terms “Company," "we”, “," "us”, “" and "our”, “Company”, “Monopar Therapeutics” and “Monopar” " refer to Monopar Therapeutics Netlist, Inc., a Delaware corporation, and its subsidiaries on a consolidated basis. Basis of Presentation We own report our results of operations on a 52- or have rights 53-week fiscal year ending on the Saturday closest to December 31, with each fiscal quarter generally divided into three periods consisting of two four-week periods and one five-week period. Our last three completed fiscal years ended on December 27, 2014, January 2, 2016 and December 31, 2016. Trademarks and Trade Names This prospectus supplement includes our trademarks or and service marks, EXPRESSvault®, NVvault®, HyperCloud® and HybriDIMM™, which are protected under applicable intellectual property laws and are the property of the Company. This prospectus supplement may also contain trademarks, service marks, trade names that we use in conjunction with and copyrights of other companies, which are the operation property of our businesstheir respective owners. Each trademarkSolely for convenience, trademarks and trade name or service mark of any other company appearing names referred to in this prospectus supplement may appear without the ® or the accompanying prospectus belongs to its holder™ symbols. Use We do not intend our use or display by us of other parties’ ' trademarks, trade names or service marks is to imply, and such use or display should not intended be construed to and does not imply imply, a relationship with, or endorsement or sponsorship by of us ofby, the trademark, trade name or service mark ownerthese other parties.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in consists of two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the specific terms of the offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectusthis offering. The second part is the accompanying prospectus, which provides is part of a registration statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus describes more general information. Generally, when we refer some of which may not apply to this “prospectus,” offering. Under this shelf registration process, we may from time to time sell our common shares having an aggregate offering price of up to $50,000,000 under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common shares that we are referring offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus together with all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation by Reference.” These documents combinedcontain important information that you should consider when making your investment decision. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any earlier dated document incorporated by reference thereinin this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or , provided that if any statement in one of these documents filed after the is inconsistent with a statement in another document having a later date hereof that are deemed —for example, a document incorporated by reference herein may modify and supersede the information in this prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statement. We urge you have not authorized anyone to carefully read this prospectus supplement and the accompanying prospectus and provide any related free writing prospectus, together with the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information other than that we have provided contained in or incorporated by reference in this prospectus supplement and the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to youfiled by us with the SEC. We have not, and Agent SVB Leerink has not, authorized anyone to provide you with different information. No We take no responsibility for, and can provide no assurance as to the reliability of any other dealer, salesperson information that others may give you. This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other person is authorized to give any information or to represent anything not contained than the securities described in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under or the solicitation of an offer to buy such securities in any circumstances and in jurisdictions where it which such offer or solicitation is lawful to do sounlawful. You should assume that the information appearing in this prospectus supplement supplement, the documents incorporated by reference and the accompanying prospectus or any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. You should also read and consider the date on information in the front of the document and that any information documents to which we have incorporated by reference is accurate only as of referred you in the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading sections entitled “Where You Can Find More Information.” As used and “Incorporation by Reference” in this prospectus supplement. Unless otherwise indicated or the context otherwise requires, the terms “we”, “us”, “our”, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing all references in this prospectus supplement to “InflaRx N.V.,” “InflaRx,” the “Company,” “we,” “our,” “ours,” “us” or the accompanying prospectus belongs similar terms refer to InflaRx N.V. and its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark ownersubsidiaries.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in consists of two parts. The first part is this the prospectus supplement, which describes our Common Stock we are the specific terms of this offering and the terms of the offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectusOffered Stock. The second part is the accompanying prospectus, which provides describes more general information. Generally, when we refer some of which may not apply to this “prospectus,” we are referring offering. Before you buy any shares of the Offered Stock, it is important for you to both documents combined. To the extent there is a conflict between read and consider the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplement. We urge you to carefully read this prospectus supplement and the accompanying prospectus and any related free writing prospectus, together with the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information that we have provided or incorporated by reference in this prospectus supplement and the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not, and Agent has not, authorized anyone to provide you with different information. No other dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized together with additional information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading headings “Incorporation by Reference of Information Filed with the SEC” and “Where You Can Find More Information.” As used in this prospectus supplement, . To the terms “we”, “us”, “our”, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own extent the information set forth in this prospectus supplement differs in any way from the information set forth in the accompanying prospectus or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing documents incorporated by reference in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to from a filing we made with the Securities and does not imply a relationship withExchange Commission, or endorsement the SEC, under the Securities Exchange Act of 1934, as amended, or sponsorship by us ofthe Exchange Act, prior to the date of this prospectus supplement, the trademarkinformation in this prospectus supplement will supersede such information. In addition, trade name to the extent any information incorporated by reference in this prospectus supplement or service mark ownerthe accompanying prospectus from a filing we make with the SEC after the date of this prospectus supplement adds to, updates or changes information contained in this prospectus supplement, the accompanying prospectus or an earlier filing we made with the SEC that is incorporated by reference in this prospectus supplement or the accompanying prospectus, the information in such later filing shall be deemed to modify, update and, where applicable, supersede such information in this prospectus supplement, the accompanying prospectus or the earlier filing with the SEC. In this prospectus supplement, we refer to New York Mortgage Trust, Inc., a Maryland corporation, together with its consolidated subsidiaries, as “we,” “us,” “the Company” or “our,” unless we specifically state otherwise or the context indicates otherwise, and refer to our wholly-owned taxable REIT subsidiaries as “TRSs.” In addition, the following defines certain of the commonly used terms in this prospectus supplement:

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, prospectus are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “Commission, or SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in two parts. The first part is this the prospectus supplement, which describes our Common Stock we are offering and the terms of the offering and also adds to and updates information contained in the accompanying prospectus and including the documents incorporated herein by reference into reference, which describes the accompanying prospectusspecific terms of this offering. The second part is the accompanying prospectus, including the documents incorporated therein by reference, which provides more general information. Generallyinformation about securities we may offer from time to time, when we refer some of which may not apply to this “prospectus,” we are referring to both documents combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplementoffering. We urge you to carefully read this prospectus supplement and the accompanying prospectus and any related free writing prospectus, together with and the information documents incorporated by reference herein and therein by reference as described under the heading “Incorporation of Information by Reference,” therein, before buying any of our Common Stock the securities being offeredoffered under this prospectus supplement. This prospectus supplement may add or update information contained in the prospectus and the documents incorporated by reference therein. To the extent that any statement we make in this prospectus supplement is inconsistent with statements made in the accompanying prospectus or any documents incorporated by reference therein that were filed before the date of this prospectus supplement, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying prospectus and such documents incorporated by reference therein. If any statement in one of these documents is inconsistent with a statement in another document having a later date – for example, a document incorporated by reference in the accompanying prospectus – the statement in the document having the later date modifies or supersedes the earlier statement. You should rely only on the information that we have provided contained or incorporated by reference in this prospectus supplement and the accompanying prospectus and prospectus, or contained in any related free writing prospectus that we may authorize to be provided to youprepared by us or on our behalf. We have not, and Agent the placement agent has not, authorized anyone to provide you with different information. No If anyone provides you with different or inconsistent information, you should not rely on it. The distribution of this prospectus supplement and sale of these securities in certain jurisdictions may be restricted by law. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. Persons in possession of this prospectus supplement or the accompanying prospectus are required to inform themselves about and observe any such restrictions. This prospectus supplement and the accompanying prospectus are not, and under no circumstances are to be construed as, an advertisement or a public offering of securities in Israel. Any public offer or sale of securities in Israel may be made only in accordance with the Israeli Securities Law, 5728-1968, or the Securities Law (which requires, among other dealerthings, salesperson the filing of a prospectus in Israel or other person is authorized to give any an exemption therefrom). The information or to represent anything not contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus or prospectus, and in any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and have authorized for use in jurisdictions where it is lawful to do so. You should assume that the information in connection with this prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference offering, is accurate only as of the date of the document incorporated by reference, those respective documents regardless of the time of delivery of this prospectus supplement or the accompanying prospectus or when any sale of our securities occurs. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement, the accompanying prospectus and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, in their entirety, before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus supplement entitled “Where You Can Find More Information” and “Incorporation of Certain Documents by Reference.” This prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains contain summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated herein by reference as exhibits to the registration statement of which this prospectus supplement is a partstatement, and you may obtain copies of those documents as described below under the heading section entitled “Where You Can Find More Information.” As used We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. Certain figures included in this prospectus supplementsupplement have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables may not be an arithmetic aggregation of the figures that precede them. As used herein, and unless the context suggests otherwise, the terms “Evogene,” “we”, ,” “us”, ,” “our”, ,” “Company”, “Monopar Therapeuticsour company” and “Monoparthe company” refer to Monopar Therapeutics Evogene Ltd. and its consolidated subsidiaries, consisting of AgPlenus Ltd., Biomica Ltd., Canonic Ltd., Casterra Ag Ltd., Evogene Inc., a Delaware corporationLavie Bio Ltd. and their consolidated subsidiaries. We own References to “dollar” and “$” are to U.S. dollars, the lawful currency of the United States, and references to “NIS” are to New Israeli Shekels, the lawful currency of the State of Israel. References to our “ordinary shares” or have rights “shares” refer to trademarks or trade names that our ordinary shares, par value NIS 0.02 per share. References to our “2019 annual report” refer to our Annual Report on Form 20-F for the year ended December 31, 2019, which we use in conjunction filed with the operation of our business. Each trademarkSEC on April 27, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark owner2020.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, prospectus are part of a “shelf” registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (Commission, or SEC, on August 5, 2022 and which was declared effective by the “SEC”)SEC on August 16, utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus2022. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the terms of the this offering of our common stock and also adds to and updates the information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectus. The second part is part, the accompanying prospectus, which provides more general information, some of which may not apply to this offering. Generally, when we refer to this “prospectus,” , we are referring to both documents parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, supplement and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on the other handprospectus, you should rely on the information in this prospectus supplement. Additional This prospectus supplements or documents filed after supplement and the date hereof that are deemed incorporated by reference herein may modify and supersede accompanying prospectus relate to the information in this prospectus supplementoffering of shares of our common stock. We Before buying any of the shares of common stock offered hereby, we urge you to read carefully read this prospectus supplement and the accompanying prospectus and any related free writing prospectus, together with the information incorporated herein and therein by reference as described below under the heading “Incorporation of Certain Information by Reference,.” before buying any of our Common Stock being offeredThis prospectus supplement contains information about the common stock offered hereby and may add to, update or change information in the accompanying prospectus. You should rely only on the information that we have provided contained in, or incorporated by reference in into, this prospectus supplement and the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to youprospectus. We have not, and Agent Ladenburg has not, authorized anyone to provide you with different or additional information. No other dealer, salesperson We are not making offers to sell or other solicitations to buy our common stock in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is authorized not qualified to give any information do so or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize anyone to be provided whom it is unlawful to you. You must not rely on any unauthorized information or representation. This prospectus supplement is make an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do soor solicitation. You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the respective document and that any information that we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement or the accompanying prospectus or the time of any sale of our common stock. This prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains contain summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated herein by reference as exhibits to the registration statement of which this prospectus supplement is a partstatement, and you may obtain copies of those documents as described below under the heading section entitled “Where You Can Find More Information.” As used We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. This prospectus supplement and the accompanying prospectus contain and incorporate by reference market data and industry statistics and forecasts that are based on independent industry publications and other publicly-available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus supplement, the terms accompanying prospectus or the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the headings “we”, “us”, “our”, “Company”, “Monopar TherapeuticsRisk Factors” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or and the accompanying prospectus, and under similar headings in the other documents that are incorporated herein by reference. Accordingly, investors should not place undue reliance on this information. Unless the context otherwise requires, in this prospectus supplement the “Company,” “we,” “us,” “our” and similar names refer to Salarius Pharmaceuticals, Inc. and its subsidiaries. “Salarius Pharmaceuticals,” “SLRX” and the Salarius logo are our trademarks. This prospectus supplement and the accompanying prospectus belongs to its holderand the documents incorporated by reference herein and therein may also contain trademarks and trade names that are the property of their respective owners. Use We do not intend our use or display by us of other partiescompanies’ trademarkstrade names, trade names trademarks or service marks is not intended to and does not imply a relationship relationships with, or endorsement endorsements or sponsorship by of us ofby, these other companies. On June 14, 2024, we filed a Certificate of Amendment to our restated certificate of incorporation, as amended, with the trademarkSecretary of State of the State of Delaware to effect a 1-for-8 reverse stock split of our issued and outstanding shares of common stock, trade name or service mark ownerpar value $0.0001 per share, which became effective on June 14, 2024. All historical share and per share amounts reflected throughout this report have been adjusted to reflect the reverse stock split.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, base prospectus are part of a “shelf” registration statement on Form S-3 (File No. 333-235791236735) that we filed with the U.S. Securities and Exchange Commission (Commission, or the “SEC”),” on February 28, utilizing a “shelf” registration process. Under the shelf registration process2020, we may offer which was amended on March 13, 2020 and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectusdeclared effective on March 19, 2020. This document is in two parts. The first part is this prospectus supplement, which supplement describes our Common Stock we are offering and the specific terms of the this offering and also adds to and updates information contained in the accompanying base prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying base prospectus. The second part is the accompanying base prospectus, which including the documents incorporated by reference, provides more general information. Generally, when we refer to this “prospectus,” we are referring to both documents combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying base prospectus or in any earlier dated document incorporated by reference thereinthat was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or If any statement in one of these documents filed after the is inconsistent with a statement in another document having a later date hereof that are deemed — for example, a document incorporated by reference herein may modify and supersede in the information accompanying base prospectus — the statement in this prospectus supplementthe document having the later date modifies or supersedes the earlier statement. We urge you to carefully You should read this prospectus supplement and the accompanying prospectus and any related free writing base prospectus, together with including the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before buying any of our Common Stock being offeredmaking an investment decision. You should rely only on the information that we have provided contained or incorporated by reference in this prospectus supplement and the accompanying prospectus and base prospectus, along with the information contained in any related free writing prospectus that we may authorize to be provided to youhave authorized for use in connection with this offering. We have not, and Agent has not, not authorized anyone to provide you with different or additional information. No other dealerYou should assume that the information appearing in this prospectus supplement, salesperson or other person is authorized to give any information or to represent anything not contained the accompanying base prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus or base prospectus, and in any related free writing prospectus that we have authorized for use in connection with this offering is accurate only as of the respective dates of those documents. Our business, financial condition, results of operations and prospects may authorize have changed since those dates. We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus supplement or the accompanying base prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be provided a representation, warranty or covenant to you. You must Moreover, such representations, warranties and covenants were accurate only as of the date when made; therefore, such representations, warranties and covenants should not rely be relied on any unauthorized information as accurate representations of the current state of our affairs. Unless we have indicated otherwise, or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information context otherwise requires, references in this prospectus supplement and the accompanying base prospectus or any related free writing to “iBio,” the “Company,” “we,” “us” and “our” refer to iBio, Inc. and its subsidiaries. This prospectus is accurate only as of supplement, the date on accompanying base prospectus and the front of the document and that any information we have incorporated by reference is accurate includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus supplement or the accompanying base prospectus are the property of their respective owners. We are offering to sell, and are seeking offers to buy, the common stock only as in jurisdictions where such offers and sales are permitted. No action has been or will be taken in any jurisdiction by us or the sales agent that would permit a public offering of the date of common stock or the document incorporated by reference, regardless of the time of delivery possession or distribution of this prospectus supplement and the accompanying base prospectus or in any related free writing prospectusjurisdiction, or other than in the United States. Persons outside the United States who come into possession of this prospectus supplement and the accompanying base prospectus must inform themselves about, and observe any sale restrictions relating to, the offering of our Common Stockthe common stock and the distribution of this prospectus supplement and the accompanying base prospectus outside the United States. This prospectus supplement contains summaries and the accompanying base prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of certain provisions contained in some of the documents described hereinan offer to buy, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety any securities offered by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.” As used in this prospectus supplement, the terms “we”, “us”, “our”, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying base prospectus belongs by any person in any jurisdiction in which it is unlawful for such person to its holder. Use make such an offer or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark ownersolicitation.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to and the accompanying prospectus that is also a part relate to an offering of our Common Stock. Before investing in our Common Stock offered by this document. This prospectus supplement, we urge you to carefully read this prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed together with the Securities information incorporated by reference as described under “Where You Can Find More Information” and Exchange Commission (the “SEC”), utilizing a “shelfIncorporation by Reference” registration processin this prospectus supplement. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectusThese documents contain important information that you should consider when making your investment decision. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the terms of the this offering and also adds to to, updates and updates changes information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectusreference. The second part is the accompanying prospectus, which provides gives more general information. Generally, when we refer to this “prospectus,” we are referring to both documents combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and supplement differs from or conflicts with the information contained in the accompanying prospectus or any earlier dated document incorporated by reference thereinreference, on the other hand, you should rely on the information in this prospectus supplementsupplement will control. Additional prospectus supplements or If any statement in one of these documents filed after the date hereof that are deemed is inconsistent with a statement in another document having a later date—for example, a document incorporated by reference herein may modify and supersede the information in this prospectus supplement. We urge you to carefully read into this prospectus supplement and or the accompanying prospectus and any related free writing prospectus, together with —the information incorporated herein and therein by reference as described under statement in the heading “Incorporation of Information by Reference,” before buying any of document having the later date modifies or supersedes the earlier statement. In deciding whether or not to invest in our Common Stock being offered. You Stock, you should rely only on the information that we have provided contained in, or incorporated by reference in into, this prospectus supplement and supplement, the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to youhave authorized for use in connection with this offering. We Neither we nor the Agents have not, and Agent has not, authorized anyone to provide you with different information. No other dealer, salesperson or other person is authorized to give any information or to represent anything make any representation other than those contained in, or incorporated by reference into, this prospectus supplement, the accompanying prospectus and any related free writing prospectus. If anyone provides you with different or inconsistent information or representation, you should not contained in this rely on them. This prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must do not rely on any unauthorized information or representation. This prospectus supplement is constitute an offer to sell only or the solicitation of an offer to buy our Common Stock offered hereby and only under in any circumstances and in jurisdictions where it which such offer or solicitation is lawful to do sounlawful. You should assume that the information appearing in this prospectus supplement and supplement, the accompanying prospectus or and any related free writing prospectus is accurate only as of and the date on the front of the document and that any information we have documents incorporated by reference is accurate only as of the date of the document incorporated by referencetheir respective dates, regardless of the time of delivery of this prospectus supplement and supplement, the accompanying prospectus or any related free writing prospectus, prospectus or any sale of our Common Stock. This prospectus supplement contains summaries Our business, financial condition, results of certain provisions contained operations and prospects may have changed materially since those dates. We further note that the representations, warranties and covenants made by us in some of the documents described herein, but reference any agreement that is made filed as an exhibit to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be any document that is incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.” As used in this prospectus supplement, the terms “we”, “us”, “our”, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in into this prospectus supplement or the accompanying prospectus belongs were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our business, financial condition, results of operations or prospects. Unless the context requires otherwise, references in this prospectus supplement to “TeraWulf,” the “Company,” the “Registrant,” “we,” “us” and “our” refer to TeraWulf Inc. together with its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark ownerconsolidated subsidiaries.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, prospectus are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (Commission, which we refer to as the “SEC”), ,” utilizing a “shelf” registration process. Under the this shelf registration process, we may offer and sell from time to time in one or more offerings offer shares of our Common Stock described in common stock having an aggregate offering price of up to $125,000,000 under this prospectus supplement at prices and on terms to be determined by market conditions at the accompanying prospectustime of each such offering. This document is We are providing information to you about this offering of our common stock in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and provides you with specific information regarding the terms of the this offering and our common stock, and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into in this prospectus supplement and the accompanying prospectus. The second part is the accompanying prospectus, which provides more general information. Generally, when we refer some of which does not apply to this “prospectus,” offering of our common stock. Before buying any of the common stock that we are referring offering, we urge you to both carefully read this prospectus supplement and all of the information incorporated by reference herein, as well as the additional information described under the headings “Where You Can Find More Information” and “Incorporation of Certain Information by Reference.” These documents combinedcontain important information that you should consider when making your investment decision. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference thereinin this prospectus supplement that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. Additional If any statement in one of these documents is inconsistent with a statement in another document having a later date—for example, a document incorporated by reference in this prospectus supplements supplement—the statement in the document having the later date modifies or documents supersedes the earlier statement. We further note that the representations, warranties and covenants made by us in any agreement that is filed after the date hereof as an exhibit to any document that are deemed is incorporated by reference herein may modify were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreement, and supersede should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the information in this prospectus supplementdate when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. We urge have not, and Cowen has not, authorized anyone to provide you to carefully read this prospectus supplement and the accompanying prospectus and with any related free writing prospectus, together with the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information other than that we have provided contained or incorporated by reference in this prospectus supplement and in the accompanying prospectus and or in any related free writing prospectus that we may authorize for use in connection with this offering and to be provided to which we have referred you. We have nottake no responsibility for, and Agent has notcan provide no assurance as to the reliability of, authorized any other information that others may give you. If anyone to provide provides you with different or inconsistent information. No other dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must you should not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do soit. You should assume that the information appearing in this prospectus supplement supplement, the documents incorporated by reference and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front their respective dates. Our business, financial condition, results of the document operations and that any information we prospects may have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stockchanged materially since those dates. This prospectus supplement contains summaries does not constitute an offer to sell or the solicitation of certain provisions contained an offer to buy any securities other than the securities described in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is a partunlawful. Unless the context otherwise indicates, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.” As used references in this prospectus supplement, the terms accompanying prospectus and the information incorporated by reference herein and therein to “Edgewise Therapeutics, Inc.,” “Edgewise,” “we”, “us”, ,” “our”, “Company”, “Monopar Therapeutics” and “Monoparus” refer refer, collectively, to Monopar Therapeutics Edgewise Therapeutics, Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark owner.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the specific terms of the this offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part is part, the accompanying prospectus, which provides gives more general informationinformation about securities we may offer from time to time, some of which does not apply to this offering. Generally, when we refer to this “prospectus,” , we are referring to both parts of this document combined together with all documents combinedincorporated by reference. To If the extent there is a conflict description of the offering varies between this prospectus supplement and the accompanying prospectus, you should rely on the information contained in this prospectus supplement. However, on the if any statement in one handof these documents is inconsistent with a statement in another document having a later date — for example, and the information contained in the accompanying prospectus or any earlier dated a document incorporated by reference therein, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplement. We urge you to carefully read into this prospectus supplement and or the accompanying prospectus and any related free writing prospectus, together with — the information incorporated herein and therein by reference as described under statement in the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offereddocument having the later date modifies or supersedes the earlier statement. You should rely only on the information that we have provided contained in or incorporated by reference in into this prospectus supplement and or contained in or incorporated by reference into the accompanying prospectus and any related free writing prospectus that to which we may authorize to be provided to have referred you. We Neither we nor ACM have not, and Agent has not, authorized anyone to provide you with information that is different. If anyone provides you with different or inconsistent information, you should not rely on it. No other dealerWe do not, salesperson or other person is authorized to give and ACM does not, take responsibility for, and can provide no assurances as to, the reliability of any information that others provide you. The information contained in, or to represent anything not contained in incorporated by reference into, this prospectus supplement and contained in, or incorporated by reference into, the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by referencerespective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or of any sale of our Common Stocksecurities. This It is important for you to read and consider all information contained in this prospectus supplement contains summaries of certain provisions contained in some of and the accompanying prospectus, including the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits herein and therein, in making your investment decision. You should also read and consider the information in the documents to the registration statement of which this prospectus supplement is a part, and we have referred you may obtain copies of those documents as described below under the heading captions “Where You Can Find More Information.” As used and “Incorporation of Documents by Reference” in this prospectus supplementsupplement and in the accompanying prospectus. We are offering to sell, and are seeking offers to buy, the terms “we”shares only in jurisdictions where such offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the shares in certain jurisdictions or to certain persons within such jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about and observe any restrictions relating to the offering of the shares and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, “us”and may not be used in connection with, “our”an offer to sell, “Company”or a solicitation of an offer to buy, “Monopar Therapeutics” any securities offered by this prospectus supplement and “Monopar” refer the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to Monopar Therapeutics Inc., a Delaware corporationmake such an offer or solicitation. We own or have rights to trademarks or various trademarks, service marks and trade names that we use in conjunction connection with the operation of our business. Each trademarkThis prospectus supplement, the accompanying prospectus and the information incorporated herein and thereby by reference may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties’ trademarks, service marks, trade name names or service mark of any other company appearing products in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to to, and does not imply a relationship with, or endorsement or sponsorship by us ofus. Solely for convenience, the trademarktrademarks, service marks and trade name names referred to in this prospectus may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, service mark ownermarks and trade names. Unless otherwise stated or the context requires otherwise, references to “BitNile,” the “Company,” “we,” “us” or “our” are to BitNile Holdings, Inc. (formerly Xxxx Global Holdings, Inc.), a Delaware corporation, and its subsidiaries.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, prospectus are part of a shelf registration statement that we filed with the Securities and Exchange Commission, or the SEC. This prospectus supplement amends and supplements the information in the prospectus filed as a part of our registration statement on Form S-3 (File No. 333-235791) that we filed 221724), which was declared effective as of December 1, 2017, or the Registration Statement. This prospectus supplement should be read in conjunction with the Securities accompanying prospectus, and Exchange Commission (is qualified by reference thereto, except to the “SEC”)extent that the information herein amends or supersedes the information contained in the accompanying prospectus. This prospectus supplement is not complete without, utilizing a “shelf” registration processand may only be delivered or utilized in connection with, the accompanying prospectus, and any future amendments or supplements thereto. Under the shelf registration process, we may Our Registration Statement allows us to offer and sell from time to time in one or more offerings our Common Stock described in a wide array of securities. In the accompanying prospectus, we provide you with a general description of the securities we may offer from time to time under our Registration Statement and other general information that may apply to this offering. Both this prospectus supplement and the accompanying prospectus include important information about us, our common stock and other information that you should know before investing. You should carefully read both this prospectus supplement and the accompanying prospectus as well as additional information described under “Where You Can Find More Information” before investing in our securities. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the terms of the offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectus. The second part is part, the accompanying prospectus, which provides more general information, some of which may not apply to this offering. Generally, when we refer to this “prospectusprospectus supplement,” we are referring to both documents combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplement. We urge you to carefully read this prospectus supplement and the accompanying prospectus and any related free writing prospectus, together with as well as the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information that we have provided or documents incorporated by reference in this prospectus supplement herein and the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to youtherein. We have not, and Agent has not, authorized anyone to provide you with different information. No other dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the If information in this prospectus supplement and is inconsistent with the accompanying prospectus, you should rely on this prospectus supplement. We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or any related free writing prospectus is covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale current state of our Common Stockaffairs. This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.” As used in this prospectus supplementprospectus, “CohBar,” the terms “Company,” “we”, ,” “our” or “us”” refers to CohBar, “our”, “Company”, “Monopar Therapeutics” Inc. COHBARTM and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to other trademarks or trade names that we use in conjunction with the operation service marks of our business. Each trademarkCohBar, trade name or service mark of any other company Inc. appearing in this prospectus supplement or are the accompanying prospectus belongs to its holder. Use or display by us property of CohBar, Inc. Trade names, trademarks and service marks of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, companies appearing in this prospectus are the trademark, trade name or service mark ownerproperty of their respective holders.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the terms of the offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectus. The second part is the accompanying prospectus, which provides more general information. Generally, when we refer to this “prospectus,” we are referring to both documents combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplement. We urge you to carefully read this prospectus supplement and the accompanying prospectus and any related free writing prospectus, together with the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information that we have provided or incorporated by reference in this prospectus supplement and the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not, and Agent has not, authorized anyone to provide you with different information. No other dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.” As used in this prospectus supplement, the terms “we”, “us”, “our”, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark owner.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, prospectus are part of a “shelf” registration statement on Form S-3 S‑3 that we initially filed with the SEC on May 28, 2021 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”256643), utilizing a “shelf” registration processand that was declared effective by the SEC on August 3, 2021. Under the shelf registration process, we may offer and sell shares of our common stock having an aggregate offering price of up to $250,000,000 from time to time in one or more offerings at prices and on terms to be determined by market conditions at the time of offering. We provide information to you about this offering of shares of our Common Stock described in the accompanying prospectus. This document is common stock in two parts. The first part is separate documents that are bound together: (1) this prospectus supplement, which describes our Common Stock we are offering the specific details regarding this offering; and the terms of the offering and also adds to and updates information contained in (2) the accompanying prospectus and the documents incorporated by reference into the accompanying prospectus. The second part is the accompanying base prospectus, which provides more general information, some of which may not apply to this offering. Generally, when we refer to this “prospectus,” we are referring to both documents combined. To If information in this prospectus supplement is inconsistent with the extent there accompanying base prospectus, you should rely on this prospectus supplement. However, if any statement in one of these documents is inconsistent with a conflict between the information contained statement in a document having a later date incorporated by reference in this prospectus supplement, on the one hand, and the information contained statement in the accompanying prospectus or any earlier dated document incorporated by reference thereinmodifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects may have changed since the earlier dates. This prospectus supplement supersedes and replaces the prospectus dated May 28, 2021 in its entirety. You should keep this prospectus supplement for future reference. You should rely only on the information contained in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering. We have not, and Xxxxxxx Xxxxx has not, authorized any other handperson to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and Xxxxxxx Xxxxx is not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplement and the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement and the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus supplemententitled “Where You Can Find More Information” and “Incorporation of Certain Information by Reference.” We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. Additional prospectus supplements or documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplement. We urge you to carefully read The distribution of this prospectus supplement and the accompanying prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement or the accompanying prospectus must inform themselves about, and observe any related free writing prospectusrestrictions relating to, together with the information incorporated herein offering of the common stock and therein the distribution of this prospectus supplement or the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information that we have provided or incorporated by reference in this prospectus supplement and the accompanying prospectus and by any related free writing prospectus that we may authorize person in any jurisdiction in which it is unlawful for such person to be provided to youmake such an offer or solicitation. We have not, and Agent has not, authorized anyone to provide you with different information. No other dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this This prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains contain summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated herein by reference as exhibits to the registration statement of which this prospectus supplement is a partstatement, and you may obtain copies of those documents as described below under the heading section titled “Where You Can Find More Information.” As used We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. This prospectus supplement and the accompanying prospectus contain and incorporate by reference market data and industry statistics and forecasts that are based on independent industry publications and other publicly-available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus supplement, the terms accompanying prospectus or the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled “Risk Factors” in this prospectus supplement and the accompanying prospectus, and under similar headings in the other documents that are incorporated herein by reference. Accordingly, investors should not place undue reliance on this information. ADMA’s name and logo are either registered trademarks or trademarks of ADMA Biologics, Inc. in the United States and/or other countries. All other trademarks, service marks or other tradenames appearing in this prospectus supplement and the accompanying prospectus are the property of their respective owners. Unless otherwise mentioned or unless the context requires otherwise, all references in this prospectus supplement and the accompanying prospectus to the “Company,” “ADMA,” “we”, ,” “us”, ,” “our”” or similar references mean ADMA Biologics, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation, and its wholly owned subsidiaries, ADMA BioCenters Georgia, Inc., a Delaware corporation (“ADMA BioCenters”), ADMA BioManufacturing, LLC, a Delaware limited liability company (“ADMA BioManufacturing”), and ADMA Plasma Biologics, Inc., a Delaware corporation (“ADMA Plasma Biologics”). We own or have rights to trademarks or This prospectus supplement and the accompanying prospectus include our trademarks, trade names that we use in conjunction with and service marks, such as “ASCENIVTM, ” “Nabi-HB®” and “BIVIGAM®,” which are protected under applicable intellectual property laws and are the operation property of our businessADMA Biologics, Inc., or its subsidiaries. Each trademarkSolely for convenience, trademarks, trade name or names and service mark of any other company appearing marks referred to in this prospectus supplement may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the accompanying prospectus belongs right of the applicable licensor to its holderthese trademarks, trade names and service marks. Use We do not intend our use or display by us of other parties’ trademarks, trade names or service marks is to imply, and such use or display should not intended be construed to and does not imply imply, a relationship with, or endorsement or sponsorship by of us ofby, the trademark, trade name or service mark ownerthese other parties.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to and the accompanying prospectus that is also a part relate to an offering of our Common Stock. Before investing in our Common Stock offered by this document. This prospectus supplement, we urge you to carefully read this prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed together with the Securities information incorporated by reference as described under “Where You Can Find More Information” and Exchange Commission (the “SEC”), utilizing a “shelfIncorporation by Reference” registration processin this prospectus supplement. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectusThese documents contain important information that you should consider when making your investment decision. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the terms of the this offering and also adds to to, updates and updates changes information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectusreference. The second part is the accompanying prospectus, which provides gives more general information. Generally, when we refer to this “prospectus,” we are referring to both documents combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and supplement differs from or conflicts with the information contained in the accompanying prospectus or any earlier dated document incorporated by reference thereinreference, on the other hand, you should rely on the information in this prospectus supplementsupplement will control. Additional prospectus supplements or If any statement in one of these documents filed after the is inconsistent with a statement in another document having a later date hereof that are deemed — for example, a document incorporated by reference herein may modify and supersede the information in this prospectus supplement. We urge you to carefully read into this prospectus supplement and or the accompanying prospectus and any related free writing prospectus, together with — the information incorporated herein and therein by reference as described under statement in the heading “Incorporation of Information by Reference,” before buying any of document having the later date modifies or supersedes the earlier statement. In deciding whether or not to invest in our Common Stock being offered. You Stock, you should rely only on the information that we have provided contained in, or incorporated by reference in into, this prospectus supplement and supplement, the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to youhave authorized for use in connection with this offering. We Neither we nor the Agents have not, and Agent has not, authorized anyone to provide you with different information. No other dealer, salesperson or other person is authorized to give any information or to represent anything make any representation other than those contained in, or incorporated by reference into, this prospectus supplement, the accompanying prospectus and any related free writing prospectus. If anyone provides you with different or inconsistent information or representation, you should not contained in this rely on them. This prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must do not rely on any unauthorized information or representation. This prospectus supplement is constitute an offer to sell only or the solicitation of an offer to buy our Common Stock offered hereby and only under in any circumstances and in jurisdictions where it which such offer or solicitation is lawful to do sounlawful. You should assume that the information appearing in this prospectus supplement and supplement, the accompanying prospectus or and any related free writing prospectus is accurate only as of and the date on the front of the document and that any information we have documents incorporated by reference is accurate only as of the date of the document incorporated by referencetheir respective dates, regardless of the time of delivery of this prospectus supplement and supplement, the accompanying prospectus or any related free writing prospectus, prospectus or any sale of our Common Stock. This prospectus supplement contains summaries Our business, financial condition, results of certain provisions contained operations and prospects may have changed materially since those dates. We further note that the representations, warranties and covenants made by us in some of the documents described herein, but reference any agreement that is made filed as an exhibit to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be any document that is incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.” As used in this prospectus supplement, the terms “we”, “us”, “our”, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in into this prospectus supplement or the accompanying prospectus belongs were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our business, financial condition, results of operations or prospects. Unless the context requires otherwise, references in this prospectus supplement to “TeraWulf,” the “Company,” the “Registrant,” “we,” “us” and “our” refer to TeraWulf Inc. together with its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark ownerconsolidated subsidiaries.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are prospectus form a part of a registration statement on Form S-3 (File No. 333-235791) S- 3 that we filed with the Securities and Exchange Commission (the “Commission, or SEC”), utilizing using a “shelf” registration process. Under process under the shelf registration processSecurities Act of 1933, we may offer and sell from time to time in one as amended, or more offerings our Common Stock described in the accompanying prospectusSecurities Act. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the terms of the this offering of common stock and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part is part, the accompanying prospectus, which including the documents incorporated by reference therein, provides more general information. Generally, when we refer to this “prospectus,” , we are referring to both documents parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any earlier dated document incorporated by reference thereinthat was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or If any statement in one of these documents filed after the date hereof that are deemed is inconsistent with a statement in another document having a later date—for example, a document incorporated by reference herein may modify in this prospectus supplement or the accompanying prospectus—the statement in the document having the later date modifies or supersedes the earlier statement. We have not, and supersede JonesTrading has not, authorized anyone to provide you with information different than or inconsistent with the information contained in or incorporated by reference in this prospectus supplement. We urge you to carefully read this prospectus supplement and , the accompanying prospectus and in any related free writing prospectusprospectus that we have authorized for use in connection with this offering. We and JonesTrading take no responsibility for, together with and can provide no assurance as to the reliability of, any other information incorporated herein that others may give you. We are not, and therein by reference as described under JonesTrading is not, making an offer to sell these securities in any jurisdiction where the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offeredoffer or sale is not permitted. You should rely only on assume that the information that we have provided or appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus prospectus, and in any related free writing prospectus that we may authorize to be provided to you. We have notauthorized for use in connection with this offering, and Agent has not, authorized anyone to provide you with different information. No other dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by referencethose respective documents, regardless of the time of delivery of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus supplement entitled “Where You Can Find More Information” and “Incorporation of Certain Information by Reference.” We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or any sale and the offering of our Common Stockcommon stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of our common stock and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement contains summaries and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of certain provisions contained an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in some of any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. Unless the documents described hereincontext indicates otherwise, but reference is made as used in this prospectus supplement and the accompanying prospectus, the terms “Ocuphire,” “the Company,” “we,” “us” and “our” refer to Ocuphire Pharma, Inc., a Delaware corporation, and its wholly-owned subsidiary on a consolidated basis. This prospectus supplement, the actual documents for complete information. All of accompanying prospectus and the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be information incorporated by reference as exhibits herein and therein contain references to the registration statement of which this prospectus supplement is a partour trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.” As used trade names referred to in this prospectus supplement, the terms “we”accompanying prospectus and the information incorporated by reference herein and therein, “us”including logos, “our”artwork and other visual displays, “Company”may appear without the ® or TM symbols, “Monopar Therapeutics” and “Monopar” refer but such references are not intended to Monopar Therapeutics Inc.indicate, a Delaware corporationin any way, that their respective owners will not assert, to the fullest extent permitted under applicable law, their rights thereto. We own or have rights to trademarks or trade names that we do not intend our use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other partiescompanies’ trademarks, trade names or service marks is not intended trademarks to and does not imply a relationship with, or endorsement or sponsorship by of us ofby, the trademark, trade name or service mark ownerany other companies.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to On August 4, 2022, we filed with the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of SEC a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time process related to time in one or more offerings our Common Stock the securities described in the accompanying prospectusthis prospectus supplement, which was automatically declared effective upon filing. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the specific terms of the this offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part is part, the accompanying prospectus, which provides gives more general information, some of which may not apply to this offering. Generally, when we refer to this “prospectus,” , we are referring to both documents parts of this document combined. To the extent there is a conflict between the information contained in In this prospectus supplement, on as permitted by law, we “incorporate by reference” information from other documents that we file with the one hand, and the SEC. This means that we can disclose important information contained in the accompanying prospectus or any earlier dated document to you by referring you to those documents. The information incorporated by reference therein, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplement. We urge you is considered to carefully read be a part of this prospectus supplement and the accompanying prospectus and any related free writing prospectus, together should be read with the same care. When we update the information contained in documents that have been incorporated herein and therein by reference as described under by making future filings with the heading “Incorporation SEC, the information included or incorporated by reference in this prospectus supplement is considered to be automatically updated and superseded. In other words, in case of Information a conflict or inconsistency between information contained in this prospectus supplement and information in the accompanying prospectus or incorporated by Reference,” before buying any of our Common Stock being offeredreference into this prospectus supplement, you should rely on the information contained in the document that was filed later. You should rely only on the information that we have provided or incorporated by reference contained in this prospectus supplement and the accompanying prospectus prospectus, including the information incorporated by reference herein as described under “Where You Can Find More Information; Incorporation of Documents by Reference,” and any related free writing prospectus that we may authorize to be provided to youprepare and distribute. We have not, and Agent the sales agent has not, authorized anyone to provide you with different informationinformation other than that contained in or incorporated by reference into this prospectus supplement, the accompanying prospectus or any free writing prospectus related hereto that we may authorize to be delivered to you. No If given or made, any such other dealerinformation or representation should not be relied upon as having been authorized by us. We may only offer to sell, salesperson and seek offers to buy any securities in jurisdictions where offers and sales are permitted. This prospectus supplement and the accompanying prospectus supplement or other person is authorized offering materials do not contain all of the information included in the registration statement as permitted by the rules and regulations of the SEC. For further information, we refer you to give any the registration statement on Form S-3, including its exhibits. We are subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and, therefore, file reports and other information or to represent anything not with the SEC. Statements contained in this prospectus supplement and the accompanying prospectus or other offering materials about the provisions or contents of any related free writing prospectus agreement or other document are only summaries. If SEC rules require that we may authorize any agreement or document be filed as an exhibit to be provided the registration statement, you should refer to you. You must not rely on any unauthorized information that agreement or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do sodocument for its complete contents. You should assume that the information in this prospectus supplement and supplement, the accompanying prospectus or any related free writing prospectus other offering materials is only accurate only as of the date on the front of the document its respective cover, and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless unless otherwise indicated. Our business, financial condition, results of the time of delivery of this prospectus supplement operations and the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stock. This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein prospects may have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Informationchanged since such date.” As used in this prospectus supplement, the terms “we”, “us”, “our”, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc., a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark owner.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, prospectus are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the U.S. Securities and Exchange Commission (Commission, or the “SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the terms of the offering of the common stock offered hereby and also adds to and updates the information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part is the accompanying prospectusprospectus dated June 14, 2021 (included in our Registration Statement on Form S-3 (File No. 333-256632)), which provides more general information. Generally, when we refer some of which may not apply to this “offering and some of which may have been supplemented or superseded by information in this prospectus supplement or documents incorporated or deemed to be incorporated by reference into this prospectus supplement that we filed with the SEC subsequent to the date of the prospectus,” we are referring to both documents combined. To the extent that there is a any conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference herein or therein, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplement. We urge you to carefully read this prospectus supplement and the accompanying prospectus and any related free writing prospectus, together with the information incorporated herein and therein by reference as described under the heading “Incorporation of Information by Reference,” before buying any of our Common Stock being offered. You should rely only on the information that we have provided or incorporated by reference contained in this prospectus supplement and supplement, contained in the accompanying prospectus and any related free writing prospectus that we may authorize to be provided to youor incorporated herein or therein by reference. We have not, and Agent has not, not authorized anyone to provide you with different informationinformation that is different. No other dealerWe are offering to sell, salesperson and seeking offers to buy, the common stock offered hereby only in jurisdictions where offers and sales are permitted. The information contained, or other person is authorized to give any information or to represent anything not contained incorporated by reference, in this prospectus supplement and contained, or incorporated by reference, in the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by referencerespective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any related free writing prospectus, or of any sale of our Common Stockshares of common stock. This prospectus supplement contains summaries of certain provisions It is important for you to read and consider all information contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a partand the accompanying prospectus, and including the documents we have referred you may obtain copies of those documents as described below under to in the heading section entitled “Where You Can Find More Additional Information.” As used in this prospectus supplement, the terms “we”, “us”, “our”, “Company”, “Monopar Therapeutics” and “MonoparIncorporation of Certain Information by Reference” refer to Monopar Therapeutics Inc., a Delaware corporationbelow. We own or have rights to trademarks trademarks, trade names, or trade names service marks that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark owner. All references in this prospectus supplement or the accompanying prospectus to “Torchlight,” the “Company,” “we,” “us,” or “our” mean Torchlight Energy Resources, Inc. and our consolidated subsidiaries, unless we state otherwise or the context indicates otherwise.

ABOUT THIS PROSPECTUS SUPPLEMENT. This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, prospectus are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), ) utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus. This document is in two parts. The first part is this prospectus supplement, which describes our Common Stock we are offering and the terms of the offering and also adds to and updates information contained in the accompanying prospectus and including the documents incorporated by reference into reference, which describes the accompanying prospectusspecific terms of this offering. The second part is part, the accompanying prospectus, which including the documents incorporated by reference, provides more general information. Generally, when we refer to this “prospectus,” , we are referring to both documents parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or any earlier dated document incorporated by reference therein, on the other hand, you should rely on the information in this prospectus supplement. Additional prospectus supplements or documents filed after the date hereof that are deemed incorporated by reference herein may modify and supersede the information in this prospectus supplement. We urge you to carefully read this prospectus supplement and the accompanying prospectus and any related free writing prospectus, together with and the information documents incorporated by reference herein and therein by reference as described under the heading “Incorporation of Information by Reference,” therein, before buying any of our Common Stock the securities being offeredoffered under this prospectus supplement. This prospectus supplement may add or update information contained in the accompanying prospectus and the documents incorporated by reference therein. To the extent that any statement we make in this prospectus supplement is inconsistent with statements made in the accompanying prospectus or any documents incorporated by reference therein that were filed before the date of this prospectus supplement, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying prospectus and such documents incorporated by reference therein. You should rely only on the information that we have provided or incorporated by reference contained in this prospectus supplement and the accompanying prospectus and any related free writing prospectus that prospectus, or incorporated by reference herein or therein. Neither we may authorize to be provided to you. We nor the underwriters have not, and Agent has not, authorized anyone to provide you with different information. No other dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to youprospectus. You must should not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only our Common Stock the securities offered hereby hereby, and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the applicable document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time date of delivery of this prospectus supplement and or the accompanying prospectus or any related free writing prospectus, or any sale of our Common Stocka security. This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.” As used in this prospectus supplementprospectus, unless the terms context indicates or otherwise requires, “the Company,” “B&W,” “we”, ,” “us”, ” or “our”, “Company”, “Monopar Therapeutics” and “Monopar” refer to Monopar Therapeutics Inc.the combined business of Xxxxxxx & Xxxxxx Enterprises, a Delaware corporation. We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Each trademark, trade name or service mark of any other company appearing in this prospectus supplement or the accompanying prospectus belongs to Inc. and its holder. Use or display by us of other parties’ trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the trademark, trade name or service mark ownerconsolidated subsidiaries.